As of data available on March 31, 2023, approximately 83% of those who received luspatercept achieved a 50% or greater reduction in RBC transfusion over 12 weeks or more compared with 66.9% with epoetin alfa, with a median duration of 130 and 77 weeks, respectively. Furthermore, regardless of baseline transfusion burden, a greater proportion of individuals receiving luspatercept achieved a 50% reduction in RBC transfusions compared with epoetin alfa at 89% and 73.9% for less than 4 units per 8 weeks, respectively, and 71.9% and 55.7% for 4 or more units per 8 weeks, respectively.1
The median number of RBC units during weeks 1 and 24 for luspatercept was 1 compared with 3 for epoetin alfa. The median time to transfusion was 155 days and 42 days, respectively. For patients who achieved RBC transfusion independence for 12 weeks or greater, 17.7% of individuals receiving luspatercept and 13.6% receiving epoetin alfa achieved 2 or more separate response episodes, according to the abstract authors, with a duration of all response being 147.9 weeks and 95.1 weeks, respectively. The mean Hb increase of 1.5 g/dL or more was achieved by 74.2% and 52.5%, respectively.1
About The Trial
Trial Name: A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve (COMMANDS)
ClinicalTrials.gov ID: NCT03682536
Completion Date (Estimated): September 2027
Previously, in 2023, results from the study showed that 58.5% achieved RBC transfusion independence of at least 12 weeks with concurrent mean Hb increases within the first 24 weeks compared with 31.2% with epoetin alfa, according to an article on Pharmacy Times. Additionally, approximately 74.1% achieved erythroid response increase of at least 8 weeks compared with 51.3%, respectively.2
Based on the initial data, the FDA approved the drug as a first-line treatment for anemia in adults without previous administration of an erythropoiesis-stimulating agent with very low- to intermediate-risk MDS who may require regular RBC transfusions.3
References
1. Zeidan AM, Platzbecker U, Della Porta MG, Santini V, et al. Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial. Journal of Clinical Oncology. May 29, 2024. Accessed June 10, 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.6565
2. Gallagher A. Luspatercept-aamt Shows Efficacy Treating Anemia Due to Myelodysplastic Syndromes. Pharmacy Times. June 19, 2023. Accessed June 10, 2024. https://www.pharmacytimes.com/view/luspatercept-aamt-shows-efficacy-treating-anemia-due-to-myelodysplastic-syndromes
3. Pharmacy Times. FDA Approves Luspatercept-aamt for First-Line Treatment of Anemia in Adults With Lower-Risk Myelodysplastic Syndromes. August 29, 2023. Accessed June 10, 2024. https://www.pharmacytimes.com/view/fda-approves-luspatercept-aamt-for-first-line-treatment-of-anemia-in-adults-with-lower-risk-myelodysplastic-syndromes